This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.
LRH-1 is a ligand-activated nuclear receptor that regulates cell proliferation, cell differentiation, and metabolic homeostasis across several organs such as the intestine, pancreas, ovaries, and liver. Given LRH-1’s central role in cellular function, it has emerged as a therapeutic target for several diseases including cancers, inflammatory bowel disease, diabetes, cardiovascular disease, and arteriosclerosis. Challenges associated with developing high-affinity ligands for this target has hampered basic biological study and therapeutic interventions. Investigators at UCSF have overcome these challenges in identifying small molecule compounds that bind to and modulate LRH-1 activity.
This novel invention provides the following advantages:
Researchers at UCSF used a disulfide-trapping screen and computational modeling to identify lead compounds that reversibly bind to the lipid binding pocket of LRH-1. These compounds may be used as a tool to study LRH-1 function and as a treatment for diseases associated with aberrant LRH-1 activity. For example, treatment of human liver cells in vitro with one lead agonist compound resulted in increased levels of target genes downstream of LRH-1.
To develop and commercialize the technology as therapy for diseases associated with nuclear receptor activity.
In vitro data available
|United States Of America||Published Application||20180243245||08/30/2018||2016-042|
LRH-1, Synthetic Ligands, Inflammatory bowel disease, Type II diabetes, Triple negative breast cancer, Pancreatic cancer